Einde keuzehulp

Meer informatie over IPF en de behandeling daarvan:

• www.longfibrose.nl: informatie van de patiëntenvereniging voor patiënten met longfibrose en hun naasten.
• www.ildcare.nl: informatie en voorlichting over interstitiële longziekten zoals longfibrose en sarcoïdose van de ILD care foundation. 

Meer informatie over samen beslissen:

• begineengoedgesprek.nl
• 3goedevragen.nl
• watertoedoet.info

Deze keuzehulp is gebaseerd op de internationale richtlijn Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in Adults (versie 2022) van de American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Asociacion LatinoAmericana de Torax (ATS/ERS/JRS/ALAT).

Ook zijn de volgende bronnen gebruikt:

1. Torrisi SE, Pavone M, Vancheri A, Vancheri C. When to start and when to stop antifibrotic therapies. European Respiratory Review. 2017;26(145). doi:10.1183/16000617.0053-2017. Hier te vinden.
2. Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal. 2017;49(2). doi:10.1183/13993003.01592-2016. Hier te vinden.
3. Guenther A, Krauss E, Tello S, et al. The European IPF registry (eurIPFreg): Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19(1). doi:10.1186/s12931-018-0845-5. Hier te vinden.
4. Kang J, Han M, Song JW. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-72607-1. Hier te vinden.
5. Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res. 2021;22(1). doi:10.1186/s12931-021-01634-x. Hier te vinden.
6. de Andrade JA, Neely ML, Hellkamp AS, et al. Effect of Antifibrotic Therapy on Survival in Patients with Idiopathic Pulmonary Fibrosis. SSRN Electronic Journal. Published online 2022. doi:10.2139/ssrn.4240847. Hier te vinden.
7. Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in idiopathic pulmonary fibrosis: Practical management recommendations for potential adverse events. Respiration. 2019;97(2). doi:10.1159/000495046. Hier te vinden
8. Noth I, Oelberg D, Kaul M, Conoscenti CS, Raghu G. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. European Respiratory Journal. 2018;52(1). doi:10.1183/13993003.02106-2017. Hier te vinden.
9. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials. European Respiratory Journal. 2016;47(1). doi:10.1183/13993003.00026-2015. Hier te vinden.
10. King TE, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2014;370(22). doi:10.1056/nejmoa1402582. Hier te vinden.